STATEMENT OF CASH FLOWS (USD $)	9 Months Ended		42 Months Ended
	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012
Net income (loss)	$ (484,472)	$ (9,519)	$ (1,731,980)
Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operations:
Amortization	98,012	102,975	222,754
Impairment loss	0	24,000	437,220
(Gain) loss on extinguishment of debt	(76,420)	0	(76,420)
(Gain) loss on conversion feature liability	0	(344,549)	0
(Gain) loss on derivatives	184,130	0	184,130
Expenses paid by shareholder	0	0	5,000
Increase (decrease) in operating capital:
Accrued interest receivable	0	0	(1,917)
Other current assets	0	0	0
Accounts payable and accrued expenses	50,253	67,354	246,442
Accrued salaries	135,000	135,000	414,194
Accrued interest payable	32,231	18,318	84,463
NET CASH USED IN OPERATING ACTIVITIES	(61,266)	(6,421)	(216,114)
Acquisition of BioCube, Inc.	0	0	3,287
NET CASH PROVIDED BY INVESTING ACTIVITIES	0	0	3,287
Issuance of Common Stock	0	0	100
Due to related party	60,000	5,000	212,880
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	60,000	5,000	212,980
Increase (Decrease) in cash and cash equivalents	(1,266)	(1,421)	153
Cash and Cash Equivalents, at Carrying Value, Beginning Balance	1,419	2,987	0
Cash and Cash Equivalents, at Carrying Value, Ending Balance	153	1,566	153
Supplemental disclosuers of cash flow information:
Interest	0	0	0
Income taxes	0	0	0
Supplemental disclosures of non-cash investing and financing activities:
Acquisition of BioCube, Inc. for common stock	0	0	8,750
Conversion of accrued interest to notes payable	8,451	22,961	31,412
Conversion of accounts payable to notes payable	12,500	22,505	172,605
Beneficial conversion feature - notes payable	187,054	101,475	288,529
Warrants issued in connection with funding fees - related party	$ 11,959	$ 6,750	$ 18,709
Conversion of notes payable, related party to common stock	169,354	0	193,146